These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 32940872)

  • 1. Short-term outcomes of induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF) in locally advanced nasopharyngeal carcinoma.
    Takamizawa S; Honma Y; Murakami N; Mori T; Oka H; Yamamoto S; Kashihara T; Ito K; Kubo Y; Ikeda A; Matsumoto F; Omura G; Kobayashi K; Itami J; Kato K; Yoshimoto S
    Invest New Drugs; 2021 Apr; 39(2):564-570. PubMed ID: 32940872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of therapeutic efficacy and toxicity of docetaxel, cisplatin, and fluorouracil (TPF)-based induction chemotherapy plus concurrent chemoradiotherapy and chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma.
    Chen R; Lu Y; Zhang Y; He R; Tang F; Yuan W; Li Y; Zhang X
    Medicine (Baltimore); 2021 Oct; 100(42):e27475. PubMed ID: 34678878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
    Zhou R; Zhu J; Chen X; Liu Y; Wang Y; Zhang T
    Clin Transl Oncol; 2020 Mar; 22(3):429-439. PubMed ID: 31165410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival benefit of adding docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma with nodal Stage N2-3.
    Kawahira M; Yokota T; Hamauchi S; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H
    Jpn J Clin Oncol; 2017 Aug; 47(8):705-712. PubMed ID: 28431119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective, Multicenter, Phase 2 Trial of Induction Chemotherapy Followed by Bio-Chemoradiotherapy for Locally Advanced Recurrent Nasopharyngeal Carcinoma.
    Ng WT; Ngan RKC; Kwong DLW; Tung SY; Yuen KT; Kam MKM; Sze HCK; Yiu HHY; Chan LLK; Lung ML; Lee AWM
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):630-638. PubMed ID: 29413277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term complications and prognostic factors in locally advanced nasopharyngeal carcinoma treated with docetaxel, cisplatin, 5-fluorouracil induction chemotherapy followed by concurrent chemoradiotherapy: A retrospective cohort study.
    Shim HJ; Kim HJ; Hwang JE; Bae WK; Chung IJ; Lee DH; Mi YT; Lee JK; Lim SC; Chung JW; Cho SH
    Medicine (Baltimore); 2020 Dec; 99(49):e23173. PubMed ID: 33285692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of GP and TPF induction chemotherapy for locally advanced nasopharyngeal carcinoma.
    Zhu J; Duan B; Shi H; Li Y; Ai P; Tian J; Chen N
    Oral Oncol; 2019 Oct; 97():37-43. PubMed ID: 31421469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis.
    Liu GY; Lv X; Wu YS; Mao MJ; Ye YF; Yu YH; Liang H; Yang J; Ke LR; Qiu WZ; Huang XJ; Li WZ; Guo X; Xiang YQ; Xia WX
    Cancer Commun (Lond); 2018 May; 38(1):21. PubMed ID: 29764487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.
    Lv X; Cao X; Xia WX; Liu KY; Qiang MY; Guo L; Qian CN; Cao KJ; Mo HY; Li XM; Li ZH; Han F; He YX; Liu YM; Wu SX; Bai YR; Ke LR; Qiu WZ; Liang H; Liu GY; Miao JJ; Li WZ; Lv SH; Chen X; Zhao C; Xiang YQ; Guo X
    Lancet Oncol; 2021 May; 22(5):716-726. PubMed ID: 33857411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02).
    Frikha M; Auperin A; Tao Y; Elloumi F; Toumi N; Blanchard P; Lang P; Sun S; Racadot S; Thariat J; Alfonsi M; Tuchais C; Cornely A; Moussa A; Guigay J; Daoud J; Bourhis J;
    Ann Oncol; 2018 Mar; 29(3):731-736. PubMed ID: 29236943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
    Wei Z; Zhang Z; Luo J; Li N; Peng X
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International randomized phase 2 study on the addition of docetaxel to the combination of cisplatin and 5-fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents.
    Casanova M; Özyar E; Patte C; Orbach D; Ferrari A; Veyrat-Follet C; Errihani H; Pan J; Zhang L; Shen L; Grzegorzewski KJ; Varan A
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):289-98. PubMed ID: 26666649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine combined with cisplatin vs. taxane, cisplatin, and fluorouracil in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective case-control study.
    Huang YM; Qiao SQ; Lu L; Chen WP; Li SL; Qi CH
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(14):7655-7663. PubMed ID: 32744691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II multicenter randomized controlled trial to compare standard chemoradiation with or without recombinant human endostatin injection (Endostar) therapy for the treatment of locally advanced nasopharyngeal carcinoma: Long-term outcomes update.
    Li Y; Tian Y; Jin F; Wu W; Long J; Ouyang J; Zhou Y
    Curr Probl Cancer; 2020 Feb; 44(1):100492. PubMed ID: 32035692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials.
    Kong L; Zhang Y; Hu C; Guo Y; Lu JJ
    Cancer; 2017 Jun; 123(12):2258-2267. PubMed ID: 28192641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing long-term efficacy and safety of GP versus TPF sequential chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis.
    Zhu Y; Xue F
    BMC Cancer; 2024 Sep; 24(1):1145. PubMed ID: 39271993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TPF induction chemotherapy followed by concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma: Long term results of a Tunisian series.
    Toumi N; Ben Kridis W; Mnejja W; Bouzguenda R; Khanfir A; Ghorbel A; Daoud J; Frikha M
    Cancer Radiother; 2018 May; 22(3):216-221. PubMed ID: 29650387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction TPF chemotherapy followed by CRT with fractionated administration of cisplatin in patients with unresectable locally advanced head and neck cancer.
    Okano S; Enokida T; Onoe T; Ota Y; Motegi A; Zenda S; Akimoto T; Tahara M
    Int J Clin Oncol; 2019 Jul; 24(7):789-797. PubMed ID: 30796560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can Epstein-Barr virus-deoxyribonucleic acid load after induction chemotherapy combined with American Joint Committee on Cancer stage determine the chemotherapy intensity of locally advanced nasopharyngeal carcinoma?
    Zhang Q; Peng ZW; Gu ZS; Wang Y; He F; Zhao WB; Luo W; Mei YY
    Cancer Med; 2023 Jan; 12(1):223-235. PubMed ID: 35674137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial.
    Sun Y; Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J
    Lancet Oncol; 2016 Nov; 17(11):1509-1520. PubMed ID: 27686945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.